Abstract. Programmed cell death 5 (PDCD5) is a novel apoptosis-promoting protein. Recently, a decreased expression of PDCD5 has been found in several types of human tumors. However, the expression level of PDCD5 in human gliomas has not been investigated. In the present study, we examined the expression of PDCD5 in 88 human glioma samples at both mRNA and protein levels by RT-PCR, Western blotting and immunohistochemistry. We found that 53.3% (16/30) of the glioma samples had a reduced expression of PDCD5 mRNA and 70.5% (62/88) had a reduced expression of the PDCD5 protein as compared to normal brain tissue. Furthermore, we studied the correlation of the expression level of PDCD5 with the clinicopathological grade and survival of patients with astrocytomas. Although longitudinal studies of a cohort of patients with astrocytoma revealed that PDCD5 expression was not able to predict clinical outcome (p>0.05), a decreased expression of PDCD5 correlated significantly with high-grade astrocytomas (p<0.001). In conclusion, our data suggest that reduced PDCD5 expression may contribute to the pathogenesis of human gliomas.
Introduction
Programmed cell death 5 (PDCD5), also designated as TF-1 cell apoptosis-related gene-19 (TFAR19), is a strong candidate of apoptosis-regulating proteins because of its known role in programmed cell death (1) . Transient or stable overexpression of PDCD5 in TF-1, MGC-803 and HeLa cells enhances programmed cell death triggered by growth factor withdrawal or serum withdrawal from a culture medium (1) (2) (3) and increases TAJ/TROY-induced paraptotic cell death (4) . Recent studies have shown that the expression of PDCD5 mRNA or protein is down-regulated in certain human tumor tissues, such as gastric cancer (5), lung cancer (6), renal clear cell carcinoma (7) , cervical cancer (8) , hepatocellular carcinoma (9), acute and chronic myeloid leukemia (10) . Additionally, the result from a whole-genome scan of lung cancer demonstrates that patients with genotype GG or GC for SNPs of the 5' region of PDCD5, compared to those with a common genotype CC show an increased risk of lung cancer and a higher incidence of poor clinical stage disease and short-term survival rate, suggesting PDCD5 may represent a novel tumor suppressor gene influencing lung cancer (6) . However, PDCD5 expression in other tumors remains unclear.
Human glioma is one of the most frequent primary tumors of the central nervous system. Nearly half of them are malignant and their treatment represents one of the most formidable challenges in clinical medicine. Over the past two decades, the overall survival rate of patients with gliomas has hardly improved and only ~2% of patients aged 65 years or older survived for >2 years (11, 12) . Therefore, new diagnostic and therapeutic strategies are required in order to control this devastating disease. Recently, considerable progress has been made in understanding the genetic alterations that are associated with gliomas, including oncogenes and tumor suppressor genes (13, 14) . To date, however, the role of PDCD5 in human glioma has not been investigated.
In this study, the status of PDCD5 expression in 88 primary gliomas was examined by means of RT-PCR, Western blotting and immuohistochemistry. Furthermore, we analyzed the association of PDCD5 expression with clinopathological features and survival of patients.
Materials and methods
Cell lines and carcinoma specimens. U251 and U87 cell lines derived from gliomas were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, P.R. China). They were cultured and maintained in Dulbecco's RNA isolation and RT-PCR. Total RNAs were extracted from 30 frozen glioma specimens, three frozen normal tissue specimens and two glioma cell lines (U251 and U87) using a modified TRIzol one-step extraction method (Sangon Biotech Co., Ltd) (15, 16) . cDNA was synthesized using the ReverseTranscribe kit (Promega Co.) according to manufacturer's instructions. The reaction was performed at 70˚C for 10 min and then at 42˚C for 1 h, followed at 95-99˚C for 5 min to stop the reaction. PCR was performed using PDCD5 specific primers (sense 5'-CCA TGG CGG ACG AGG AGC TTG-3', and anti-sense 5'-TCA ATA ATC GTC ATC TTC ATC-3') for 30 cycles at 94˚C for 30 sec, 58˚C for 30 sec and 72˚C for 30 sec followed by an extension cycle at 72˚C for 7 min.
SDS-PAGE and Western blotting.
The proteins were extracted from tissue samples and glioma cell lines using a modified TRIzol one-step extraction method (15, 16) . The concentration of the protein was determined by Bradford analysis. The protein extract was dissolved in a loading buffer (1 mM Tris·Cl, 3% SDS, 60% glycerol and 75 mM DTT) and each sample was analyzed by SDS-PAGE on a 15% gel. The PVDF membrane was incubated with mouse anti-human PDCD5 (1:1000) or rabbit anti-human ß-actin (1:2000) at 4˚C overnight. Immunoreactive bands were visualized using the enhanced chemiluminescence method according to the manufacturer's instructions (ECL, Amersham Biosciences, UK).
Immunohistochemistry. Paraffin sections (5 μm) were stained with an anti-PDCD5 antibody by incubating overnight at 4˚C. Secondary staining with biotin-conjugated anti-mouse IgG and tertiary staining with HRP-conjugated strepto-avidin were performed using an ABC kit and a DAB Peroxidase Substrate kit (Maixin Co., Fuzhou, P.R. China). The sections were counterstained with hematoxylin. Negative controls for the specificity of immunohistochemical reactions were performed by replacing the primary antibody with IgG of nonimmunized mice.
Scoring of PDCD5 immunohistochemical reaction staining.
Cytoplasmic and nuclear expression of PDCD5 was assessed by two independent observers who were blinded to the patient's outcome information. A semi-quantitative scoring system was adopted to evaluate the result of immunohistochemistry and a Table I . Correlation between PDCD5 protein expression and clinicopathological features of glioma patients. 
consensus score was reached for each section. The PDCD5 signal was recorded in four grades according to the intensity of the staining: 0, 1+, 2+ and 3+. The percentages of PDCD5-positive cells were also recorded in four categories: 1 (0-25%), 2 (26-50%), 3 (51-75%) and 4 (76-100%) (17) . In the cases with a discrepancy between the two observers, the average score from the two tissue cores was taken as the final score. The sum of the intensity and percentage scores is used as the final staining score. The final staining pattern of the biopsies was defined as follows: 1, negative or faint positive; 2, weak; 3, moderate; and 4, strong. Scores 1 and 2 are classified as low expression of PDCD5; whereas 3 and 4 are classified as high expression (overexpression) of PDCD5.
Statistical analysis. The χ 2 test was used to compare the expression of PDCD5 with clinicopathological parameters. Cumulative survival time was calculated by the Kaplan-Meier method and analyzed by the log-rank test. P<0.05 was considered statistically significant. The calculations were performed using the SPSS statistical software.
Results

Expression of PDCD5 in human glioma-derived cell lines.
To explore the potential roles of PDCD5 in gliomas, the status of PDCD5 expression in glioma-derived cell lines, U251 and U87, was examined by RT-PCR and Western blotting. As shown in Fig. 1 PDCD5 mRNA and protein, whereas the U87 cell line showed low levels of PDCD5 expression, suggesting that the expression of PDCD5 may be reduced in human gliomas.
Expression of PDCD5 in human primary gliomas. Then, the expression of PDCD5 mRNA and protein in human primary gliomas was examined by RT-PCR and Western blotting. Compared to three normal brain samples, 53.3% (16/30) of the human primary glioma samples expressed low or no PDCD5 mRNA ( Fig. 2A and B) (Table II) , while 83.3% (25/30) of them showed a reduced expression of the PDCD5 protein ( Fig. 2C and D) (Table II) . Additionally, we examined PDCD5 expression by immunohistochemisty. As shown in Fig. 3A , PDCD5 was predominantly expressed in the cytoplasm, although a low level of PDCD5 was also detected in the nucleus, as previously reported (18) . In non-tumorous brain tissues, there was a strong positive staining of PDCD5 (Fig. 3A-a) . In grade I-II of the glioma samples, there was a moderate positive staining of PDCD5 (Fig. 3A-b) . In contrast, in grade III of the glioma samples, there was a weak positive staining of PDCD5 (Fig. 3A-c) . In grade IV of the glioma samples, faint or no staining of PDCD5 was detected in the tumor cells (Fig. 3A-d) . The positive rate and intensity of PDCD5 expression were further analyzed as described in Materials and methods. A correlation of the expression levels of PDCD5 with clinicopathological grades of gliomas is shown in Fig 3B. Glioma samples (70.5%) (62/88) showed low or no expression Table II 
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The pathological analysis was performed according to the new World Health Organization (WHO) criteria. The levels of PDCD5 mRNA were analyzed by semi-quantitative RT-PCR according to OD values of PDCD5 mRNA expression normalized to ß-actin: -, not detected; +, 0 to 0.25; ++, 0.25 to 0.5 and +++, >0.5. Expression of the PDCD5 protein was detected by Western blotting semi-quantitatively according to OD values of PDCD5 protein expression normalized to ß-actin: -, not detected; +, 0 to 0.25; ++, 0.25 to 0.5; +++, 0.5 to 0.75 and ++++, >0.75. (Table I) . These results indicate that the expression of PDCD5 was frequently reduced in human primary gliomas.
Correlation of the expression level of PDCD5 with the clinicopathological grade and survival of patients with primary gliomas. To determine the clinical value of PDCD5 expression in primary gliomas, we examined the correlation of PDCD5 expression with the clinicopathological grade and survival of patients with gliomas. The results showed that there was no significant correlation between PDCD5 expression and gender, age or histological type (Table I) . However, the expression of PDCD5 correlated significantly with the pathological grade (p<0.001). Within the same histological glioma (astrocytoma) type, the rate of reduced expression of PDCD5 was higher in high-grade gliomas (III-IV) than that in low-grade gliomas (I-II) (86.0%, 43/50 vs. 45.2%, 14/31) (Table I) . Furthermore, we analyzed the association of the overall survival of the astrocytoma patients (n=81) with low or high PDCD5 expression. However, as judged by the Kaplan-Meier analysis (Fig. 4A) , PDCD5 expression had no statistically significant impact on the prognosis of astrocytoma patients (p>0.1). Similarly, no progonostic value of PDCD5 expression can be detected for patients with same grades of gliomas (I-II, n=31; III-IV, n=50) ( Fig. 4B and C) . 
Discussion
In the present study, we demonstrated for the first time, that PDCD5 expression decreased significantly in gliomas compared with non-tumorous brain tissues, which significantly correlated with the grades of the gliomas. However, longitudinal studies of a cohort of patients revealed that PDCD5 expression had no statistically significant impact on the prognosis of astrocytoma patients.
The expression of PDCD5 increases during the apoptotic process of cells induced by cytokine withdrawal (1) . The overexpression of PDCD5 promotes programmed cell death triggered by certain stimuli (2, 3) . Importantly, blocking the activity of PDCD5 by introducing an anti-PDCD5 antibody into cells is able to suppress the etoposide-induced apoptosis of tumor cells (3). These reports demonstrate that PDCD5 plays a significant role in apoptotic and paraptotic cell deaths. It is well known that the dysfunction of cell apoptosis leads to uncontrolled cell growth, such as cancer (19, 20) . In the present study, we demonstrated that the expression of PDCD5 mRNA or protein decreased significantly in primary gliomas, compared with normal brain tissues (Figs. 2 and 3 ) (Table II) , which is consistent with other reports of cervical cancer (8) , gastric tumor (5), lung cancer (6) and chronic myelogenous leukemia (10) . Thus, the results suggest that a low expression of PDCD5 in tumors may affect the growth of tumors including glioma by interfering with programmed cell death. However, more studies are needed to clarify this issue.
To date, the clinical significance of PDCD5 downregulation in tumors is unclear. Previous reports showed that the decreased expression of PDCD5 in renal clear cell carcinomas significantly correlated with the high-grade tumor (7) and that the patients with low PDCD5-expressing gastric tumor have a shorter survival period (5) . Astrocytic tumors, the most common type of gliomas, develop from a type of star-shaped cell called astrocytes. To clarify the clinical significance of PDCD5 down-regulation in gliomas, we divided astrocytic tumors into two groups: low-grade group (grades I and II ) and high-grade group (grade III and IV) according to the World Health Organization (WHO) classification system and then analyzed the association of PDCD5 expression in two groups of astrocytomas with clinicopathological characteristics and survival of patients by a three-year follow-up investigation. Our results demonstrated that the reduced expression of PDCD5 correlated significantly with high-grade astrocytoma. In general, low-grade astrocytomas are usually slow growing and are not likely to spread, whereas high-grade astrocytomas grow rapidly and have a poor prognosis. However, longitudinal studies of a cohort of patients revealed that the status of PDCD5 expression has no significant correlation with the prognosis of patients. The lack of correlation is most likely explained by the multiple prognostic factors involved in the disease, such as diagnosis or surgery time and the complex network of other genes, which are involved in the tumor formation. However, the lack of prognostic impact in our study population does not exclude a potential role for PDCD5 in the pathogenesis of human gliomas.
In conclusion, we have demonstrated that a decreased expression of PDCD5 correlated significantly with highgrade astrocytomas. Although the expression of PDCD5 did not influence clinical outcome in our study, PDCD5 may serve as a novel therapeutic target for the treatment of cancer. 
